Takahiro Sumimoto

Has grant

Assistant Professor

Oita University Hospital
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Takahiro Sumimoto is the chief pharmacist at Oita University Hospital in Japan. His research primarily focuses on oncology, pharmacotherapy, and the clinical applications of drug monitoring, as evidenced by his recent publications on cancer cachexia, immune checkpoint inhibitors, and the pharmacokinetics of tyrosine kinase inhibitors. He is dedicated to advancing the understanding of pain management and treatment efficacy in cancer patients.

Recent Grants

Grant: Open

がん悪液質の進行に伴うCYP3AおよびOATP1B活性の変動要因の解明

Open Date: 2024-04-01

Close Date: 2027-03-31

Grant: Close

アナモレリンの治療効果関連因子の探索~グレリン濃度及び薬物動態に着目した検討~

Open Date: 2022-04-01

Close Date: 2023-03-31

Grant: Close

癌悪液質の進行度とCYP3AおよびOATP1B活性の関連性の解明

Open Date: 2021-04-01

Close Date: 2022-03-31

Articles (9)

Year:

2026

Genetic factors, inflammatory cytokines such as interleukin (IL)‐6 and tumor necrosis factor‐α (TNF‐α), and uremic substances such as 3‐carboxy‐4‐methyl‐5‐propyl‐2‐furanpropanoic acid (CMPF) have been reported to affect organic anion transporting polypeptide (OATP)1B1 transport activity. However, the relationship between OATP1B1 transport activity and these factors in patients with cancer cachexia has not been reported. This study aimed to identify the factors contributing to individual differences in OATP1B1 transport activity in patients with cancer cachexia, using coproporphyrin‐I (CP‐I) as an endogenous biomarker of OATP1B1 transport activity. The study recruited 114 patients with cancer cachexia who satisfied the selection criteria. The subjects were classified into pre‐cachexia, cachexia, and refractory cachexia. Median [interquartile range] plasma CP‐I level was higher in patients with pre‐cachexia (0.91 [0.67–1.12] ng/mL) compared with the data in the general population reported previously and tended to be higher in patients with refractory cachexia (1.06 [0.78–1.64] ng/mL) than in those with cachexia (0.87 [0.62–1.07] ng/mL), suggesting that OATP1B1 transport activity may decrease with the progression of cancer cachexia. Plasma CP‐I correlated positively with IL‐6 and TNF‐α concentrations but did not correlate with OATP1B1 polymorphisms or CMPF concentration, which have been reported to reduce transport activity. Multiple regression analysis using the forced entry method identified refractory cachexia as a significant factor independently affecting plasma CP‐I concentration. These findings suggest that the reduction in OATP1B1 transport activity in patients with cancer cachexia may be attributed to inflammatory cytokines or some other factors that are elevated by cancer cachexia progression, rather than OATP1B1 polymorphisms and CMPF.

Year:

2025

Aims This study aimed to determine the clinical relevance of the influence of coadministration of immune checkpoint inhibitors (ICIs) on the analgesic effects of opioids, focusing on the amount of change in opioid dosage. Methods This study used data from patients who used opioids during anticancer therapy at the Oita University Hospital between September 2014 and October 2023. The primary outcome measure was the amount of change in morphine mg equivalent opioid dose during the period of anticancer therapy. Propensity score matching was performed to reduce confounding effects. Results The study enrolled 235 patients; 101 received ICI and 134 received no ICI. Before propensity score matching, there were significant differences between the ICI and non‐ICI groups in lines of anticancer therapy, type of primary cancer, body mass index, maximum opioid dose and the amount of change in opioid dose. Following propensity score matching, 73 patients each were included in the ICI and non‐ICI groups. Analysis of the propensity score‐matched cohort showed a significant increase in the median amount of change in opioid dose in ICI group vs non‐ICI group (22.5 vs . 15.0 morphine mg equivalents, interquartile range; 0.0, 40.0 vs . 0.0, 30.0, P = .044). Multiple regression analysis identified ICI administration and body mass index as significant independent factors associated with the amount of change in opioid dose ( P = .014 and .027, respectively). Conclusions ICI administration significantly increased opioid dosage regardless of patient background. Our findings would provide valuable insight into future pain management strategies.

Year:

2025

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (2)

Naoki Yoshikawa

-

JAPAN
View details

Hiroki Itoh

Professor

Oita University Hospital

JAPAN
View details